Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis

Completed · Phase 2

Conditions studied: Plaque-type Psoriasis

In brief

This is a multicenter, open-label study to assess systemic plasma levels of calcitriol, calcium homeostasis and safety in adults with plaque-type psoriasis under conditions of maximized use of CD 2027 3µg/g oily spray twice daily (6 g daily), applied to 20% of BSA for 3 weeks. There are a total of six visits: Pre-treatment period (Day -15, Day -8 and Day -1) and Treatment period (Day 1/ Baseline, Day 15 and Day 22).

Key facts

Study ID

NCT00763503

Run by

Galderma R&D

People needed

26

Starts

2008-09-01

Expected to finish

2009-02-01

Last updated by the study team

2021-02-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of plaque-type psoriasis involving 10% - 20% of body surface area (BSA), with a Global Severity Score of at least 3 (moderate)

You may not qualify if…

• Other type of psoriasis (other than plaque)
• Significant abnormal lab findings
• Secondary hyperparathyroidism
• Vit D deficiency
• Hypercalcemia

Where it is running

• Burke Pharmaceutical Research — Hot Springs, Arizona, United States
• DermResearch — Austin, Texas, United States
• J & S Studies — Bryan, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.